LRRK2 and pulmonary fibrosis: LRRK2 inhibition also blocks exocytosis of endo-lysosome–related organelles in type II pneumocytes of the lung that secrete pulmonary surfactant; prolonged inhibition of this process causes pulmonary fibrosis, a side effect that is carefully monitored in ongoing LRRK2 inhibitor clinical trials.